Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
This is a summary of recent ratings and recommmendations for Cardiol Therapeutics and Adaptive Biotechnologies, as provided by MarketBeat.
|Strong Buy Ratings
Cardiol Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 136.22%. Adaptive Biotechnologies has a consensus target price of $7.67, suggesting a potential upside of 94.09%. Given Cardiol Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Adaptive Biotechnologies.
Earnings & Valuation
|Earnings Per Share
Cardiol Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.
This table compares Cardiol Therapeutics and Adaptive Biotechnologies’ net margins, return on equity and return on assets.
|Return on Equity
|Return on Assets
Volatility & Risk
Cardiol Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Institutional and Insider Ownership
10.4% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of Adaptive Biotechnologies shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 5.2% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cardiol Therapeutics beats Adaptive Biotechnologies on 7 of the 13 factors compared between the two stocks.
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.